chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a nurse practitioner concerning a female who on unspecified date was vaccinated IM with the third dose of GARDASIL. It was reported that the patient got her third dose of GADASIL and began having vaginal pain. The patient sought unspecified medical attention. At the time of this report, the patient had not recovered. Additional information has been requested.
Case number PHEH2013US024876 is an initial spontaneous report received from a pharmacist on 26 NOV 2013. This report refers to a 39-year-old adult female patient. Her medical history and concomitant medications were not reported. She was vaccinated with FLUVIRIN 2013-2014 (batch number: 131001, expiry date: MAY 2014) intramuscularly at a dose of 0.5 ml on 24 NOV 2013. On 25 NOV 2013, after vaccination she experienced nausea and complained of a metallic taste. She did not visit any physician or sought medical care from a health care professional at the time of reporting. The outcome of the event was condition unchanged. The seriousness and causality of the events was not reported.
This case was reported by a pharmacist via call center representative and described the occurrence of fever in a adult male patient who received SHINGRIX. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fever and rash. On an unknown date, the outcome of the fever and rash were unknown. The reporter considered the fever to be related to SHINGRIX. The reporter considered the rash to be unrelated to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The pharmacist reported that a patient had a fever and a rash on the back of his knee following SHINGRIX.
Narrative: COVID infection following COVID vaccine series 12/29, Pfizer, dose #1 01/19, Pfizer, dose #2 08/04 pt cc: chills, cough, diarrhea, fatigue, fever, headache, myalgias, rhinorrhea exposure: unknown 08/04 COVID swab, result: detected 08/04 - 08/09 pt continue to have symptoms 08/04 SARS-COV-2 Variant Sequencing results: pending 08/10 pt reports mild symptoms, clinically resolved
Moderna COVID-19 Vaccine EUA  Hello  After the  Covid Vaccine I?ve felt really low and no energy.  My doctor has diagnosed with low Testosterone count.  No one will say it?s related to the vaccine. I thought I?d just share my outcome.  It might be coincidence, but if a few other have the same coincidence.  Maybe this report is a waste of your time maybe not.   So my outcome is low testosterone. Thank you.
Local reaction left thigh, red area 4.5 x 5 inches started 24 hours after vaccine seen in clinic 2 days after will f/u tomorrow.
A report was received from a health care professional on 12/5/03 concerning a 2 year old female vaccinee who inadvertently received Fluvirin on the same day. On 12/5/03, a vaccinee inadvertently received Fluvirin. At the time of the report no adverse events had been reported. There was insufficient information to determine the reporter's causality assessment. Update 2/6/04: A follow up report was received from a health care professional indicating that the vaccinee received Fluzone on 1/5/04. No adverse effects were reported. Follow up pending.
pt recv vax 20MAY96 & exp lip swelling w/in 30min of vax;there were no sx of anaphylaxis, no SOB, & the swelling resolved spontaneously;
Patient came 6/11/03 with severe swelling, pain at injection site. referred to PMD for evaluation and treatment
Missed her appointment second dose on 9 Apr 2021 because she is wheel-chair bound and did not have someone to transport her to the appointment; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed her appointment second dose on 9 Apr 2021 because she is wheel-chair bound and did not have someone to transport her to the appointment) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     Concomitant products included PREDNISONE for Arthritis, ATENOLOL and AMLODIPINE for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed her appointment second dose on 9 Apr 2021 because she is wheel-chair bound and did not have someone to transport her to the appointment). On 09-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed her appointment second dose on 9 Apr 2021 because she is wheel-chair bound and did not have someone to transport her to the appointment) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
The 2nd morning after getting shot 2 of the Moderna vaccine, I woke up and noticed a deep red rash on my neck, shoulders and torso. I typically get this kind of rash when I have an upper respiratory infection/ear infection/sinus infection. This is my body's response to infection and virus. I assume my body is treating the vaccine like an infection. I am taking Benadryl for the reaction. I do not have any other adverse side effects, but do feel fatigue, minimal body aches and headache. I am taking Tylenol for that.
This literature marketed report as received from a physician refers to 5 patients of unknown demography. The patient's current condition included STAT3 deficient hyper IgE syndrome. On an unknown date, the 5 patients were vaccinated with PNEUMOVAX 23. On an unknown date, the 5 patients were hospitalized for IV antibiotics. The outcome of the event was unknown. The reporter assessed the causality of the event to be related to the suspect therapy. This case is linked to case # 1502USA008319 and case # 1502USA008276 (same literature link). Additional information is expected.
lower dose volume administered; This spontaneous case was reported by a pharmacist and describes the occurrence of UNDERDOSE (lower dose volume administered) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In January 2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In January 2022, the patient experienced UNDERDOSE (lower dose volume administered). In January 2022, UNDERDOSE (lower dose volume administered) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medications was reported. Pharmacist states that 27 days ago she administered a Booster dose of the Moderna Covid-19 Vaccine by mistake, instead she should have administered the complete first dose.
Approx 2 wks p/receiving a dose of Td, pt noted 4-5cm tender & red, solid area in lt arm, below original inject site; 13SEP90, MD aspirated area w/no results; On 9OCT, area was 4-cm wide & warm & tender @ site of the surgical scar;
Sharp pain in the hip/joint area.; Walk with a limp; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 (at the age of 55-year-old) as a single dose for COVID-19immunisation. The patient had no relevant medical history and had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 24Mar2021 (at the age of 54-year-old) as a single dose for COVID-19immunisation. On 17Apr2021 the patient experienced sharp pain in the hip/joint area and was not able to put pressure on the left leg due to pain. On the same day, the patient was walking with a limp and was trying to give it 24/48 hours before seeing a doctor. Therapeutic measures were not taken as a result of the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sharp pain in the hip/joint area and walk with a limp was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
THE INSURANCE COMPANY HAS NOT PAID FOR THE 2/3 HPV VACCINES DONE ON 6-13-07 AND 8-13-07. THE PROVIDER'S BILLING HAS BILLED THE INSURANCE FOR THE SAME VACCINE WITH THE BILLING CODE, BUT THE INSURANCE WILL NOT PAY. I HAVE BEEN TOLD THE INSURANCE HAS ANOTHER CODE, BUT THAT THE FDA HAS SAID THE GARDASIL VACCINE FOR HPV IS RECCOMENDED FOR FEMALES AGES 9 TO 26, SO INSURANCE COMPANIES DO NOT PAY FOR THE VACCINE IF WOMEN ARE 27 OR OLDER BECAUSE OF THE FDA STATING THE AGES 9 TO 26, EVEN IF THERE ARE WOMEN 27 AND OLDER WHO HAVE HPV AND GOT THE VACCINE, WHO NEED THEIR INSURANCE TO PAY THE BILL, LIKE MYSELF WHO IS 28. I HAVE ALSO SENT A COMPLAINT TO THE FDA AND I HAVE CALLED THE AMA. I HAVE SUFFERED CHRONIC PAIN, STRESS, ANXIETY, I HAVE BEEN ON THE PHONE WITH THE PROVIDER AND THE INSURANCE FOR HOURS ABOUT THIS. FINALLY, I FOUND OUT THE CPT CODE THE PROVIDER IS USING IS NOT FOR A SPECIFIC AGE GROUP OF 9-26, BUT JUST FOR THE HPV GARDASIL VACCINE. IT IS THE GARDASIL COMPANY AND FDA SAYING THAT IT IS FOR 9-26 THAT IS MAKING THE INSURANCE COMPANIES REFUSE TO PAY FOR WOMEN 27 AND OLDER GETTING THE VACCINE. THIS IS AN ADVERSE VACCINE EVENT AND IT IS NOT FAIR. i THINK IT IS FRAUD.
quite suddenly and all at once her left arm hurt"; lymph nodes swelled under her (left) arm; left side of her face went numb- from eyes to lips"; a very deep pain inside her chest; arm pain; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (quite suddenly and all at once her left arm hurt"), VACCINATION SITE LYMPHADENOPATHY (lymph nodes swelled under her (left) arm), HYPOAESTHESIA (left side of her face went numb- from eyes to lips"), CHEST PAIN (a very deep pain inside her chest) and PAIN IN EXTREMITY (arm pain) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for an unknown indication.     The patient's past medical history included Malignant ventricular arrhythmias.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced PAIN IN EXTREMITY (quite suddenly and all at once her left arm hurt"), VACCINATION SITE LYMPHADENOPATHY (lymph nodes swelled under her (left) arm), HYPOAESTHESIA (left side of her face went numb- from eyes to lips"), CHEST PAIN (a very deep pain inside her chest) and PAIN IN EXTREMITY (arm pain). The patient was treated with ice at an unspecified dose and frequency. On 12-Feb-2021, HYPOAESTHESIA (left side of her face went numb- from eyes to lips") had resolved. On 14-Feb-2021, PAIN IN EXTREMITY (quite suddenly and all at once her left arm hurt"), VACCINATION SITE LYMPHADENOPATHY (lymph nodes swelled under her (left) arm), CHEST PAIN (a very deep pain inside her chest) and PAIN IN EXTREMITY (arm pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       This case was linked to MOD-2021-034292 (Patient Link).
I am pregnant, due on May 20 and had the 2nd shot April 15. On the night of April 15, I experienced a slight fever of 100.5, chills, fatigure and dizziness all managed with Tylenol. On April 16 during the day I felt tired with a sore arm. Around 7 pm on April 16th I started to experience severe chest pain, it felt like heartburn/GERD but it was very very painful (8/10) and wasn't going away with tums or pepcid after about 3 hours. My doctor advised me to go to L&D at the hospital. They checked the baby who was fine and did an ecg also fine. They gave me lidocaine and milk of magnesia although by this time, around 7 hours after it started, it began to get better on its own anyway.
PT RECEIVED A FLU VACCINE AND WAS ASKED TO REMAIN IN THE WAIT AREA FOR OBSERVATION. SHORTLY AFTER (2-3 MINUTES), HE GOT UP HAVING A SUDDEN HEAT RUSH FLOWING THROUGH HIS BODY AND ASKING FOR A WET TOWEL TO APPLY BEHIND HIS NECK. HE ATTEMPTED GETTING UP AND HE FELT VERY FAINT LIKE SO HE DECIDED TO CRAWL ON THE FLOOR.  HE SAID HE FELT BETTER AFTER 2 TO 3 MINUTES. AT THE SAME TIME, EMT ARRIVED AND CHECKED HIS BLOOD PRESSURE AND PULSE. ACCORDING TO THE EMT STAFF, HIS BLOOD PRESSURE AND PULSE WERE NORMAL. WE CALLED PATIENT ABOUT 5 HOURS AFTER THE VACCINATION TO CHECK UP ON HIM, AND HIS WIFE SAID HIS IS FINE.
Pt recv vax on 11/19/98; on same day pt exp sore arm, swimming head, glassy eyes, flushed face x 1 day
Treatment of COVID-19; Treatment of COVID-19; Pfizer/BioNTech: Moderna; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP), Program ID: (005570). The reporter is the patient.  A 70-year-old male patient received BNT162b2 (BNT162B2), in Nov2021 as dose 1, single (Batch/Lot number: unknown), in left arm and in Mar2022 as dose 2, single (Batch/Lot number: unknown) at the age of 69 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), in Nov2022 as dose 3 (booster), single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "COPD" (unspecified if ongoing); "Liver chirrosis" (unspecified if ongoing); "terribly obese" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset Nov2022, outcome "unknown", described as "Pfizer/BioNTech: Moderna"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical information: Anti-viral details: Product=COVID 19 Treatment, Brand=Paxlovid, Treatment start date=Dec2022. Treatment stop date=Dec2022, Indication=Treatment of COVID-19. Pt says pt was at high risk would be an understatement. Pt have had all 4 shots and recently got Covid 19. Pt health is so bad Pt expected to die. Pt have COPD, Liver chirrosis, terribly obese, and much more. On my third day of Covid Pt began taking Paxlovid. What a relief, Pt was over Covid in 5 days. But alas, Pt rebounded 2 days later. In all Pt suffered with Covid for 2 and a half weeks. But it went away and Pt was fine. You people at Pfizer saved Pt life, Thank You, God Bless. Medical Information, Forwarded to MI, N/A, no medical inquiry asked. Other medication in 2weeks: Yes, Other medical history: Too many to list.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Itchiness on the injection site; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PRURITUS (Itchiness on the injection site) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE PRURITUS (Itchiness on the injection site). At the time of the report, INJECTION SITE PRURITUS (Itchiness on the injection site) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.
Non-ST elevation (NSTEMI) myocardial infarction Acute kidney failure, unspecified Thrombocytopenia, unspecified
got sick; tested positive for COVID19; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (got sick) and COVID-19 (tested positive for COVID19) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Apr-2021, the patient experienced ILLNESS (got sick) and COVID-19 (tested positive for COVID19). At the time of the report, ILLNESS (got sick) and COVID-19 (tested positive for COVID19) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Apr-2021, SARS-CoV-2 antibody test: unknown (Positive) COVID positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported by investigator  No treatment medications provided by the reporter.
Swollen Lymph nodes (under right arm and neck); Nausea; Tiredness; Chills; Headache; Muscle pain; Joint pain; This is a spontaneous report from a contactable consumer (patient). A 53-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number: EW0150), via an unspecified route of administration in right arm on 10Apr2021 (at the age of 53-years-old) at 10:15 at single dose for COVID-19 immunization. The patient's medical history included sleep apnea, sulfonamide allergy and prediabetes. Concomitant medications included vitamin D and vitamin C. Prior to vaccination, the patient was not diagnosed with COVID-19 and was not pregnant. The patient experienced swollen lymph nodes (under right arm and neck), nausea, chills, headache, muscle pain, tiredness, and joint pain on 11Apr2021. The events were reported as non-serious and resulted in doctor or other healthcare professional office/clinic visit. The patient received treatment of Naproxen 500mg. The patient had not been tested for COVID-19 since vaccination. The outcome of the events was reported as recovering.  No follow-up attempts are possible; No further information is expected.
No other AE.; the patient received a dose of MMRII on 6/30/2023, after the product was involved in a temperature excursion.; This spontaneous report was received from a registered nurse regarding a patient of an unknown age and gender. The patient's medical history and concurrent conditions were not reported. The patient's concomitant medications included varicella virus vaccine live (oka/merck) (VARIVAX).   On 30-JUN-2023, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (rHA) injection, 1 dose, lot #W035041, expiration date: 24-MAY-2024, administered as prophylaxis (strength, and route of administration were not provided) (Product storage error).  The improperly stored vaccine underwent a temperature excursion of 48.8 degrees Fahrenheit (F) for an unknown time, and it was unspecified previous excursions. The patient did not experience any other adverse event.  This is one of several cases received from the same reporter.; Sender's Comments:  US-009507513-2307USA006400: US-009507513-2307USA006038: US-009507513-2307USA006117: US-009507513-2307USA006253: US-009507513-2307USA006048: US-009507513-2307USA006043: US-009507513-2307USA005725:
Patient with 2 Pfizer vaccinations who admitted to hospital with complications of COVID.  Provider discharge note below:  "80 YO female h/o dementia, CAD - presented with altered mentation with cough and fever. She was found to be covid positive on the 23rd. Labs notable for elevated cardiac enzyme with imaging consistent with pulmonary embolism.    During her stay, she was treated with Remdesivir and Decadron. She was also started on heparin drip that was later transitioned to Eliquis on discharge. She was found to have new onset of acute heart failure with reduced ejection fracture. She was seen by Cardiology who started her on Coreg and Entreso. Conservative management was elected per daughter's request. Hospice care was also elected on discharge after discussion with patient's daughter."
Abnormal taste in the back of my mouth.  Has been going on since vaccination sometimes more pronounced then others. Almost like a constant bitterness taste .
This spontaneous report as received from a physician who heard about the experience from another physician, via company representative refers to a patient of unknown age and gender. There was no information about concomitant medications and pertinent medical history reported. On an unknown date, the patient was vaccinated with GARDASIL 9 (first dose) intramuscular (dose, lot#, expiration date were not reported). On an unknown date, reported as "within seconds after being administered the first dose of GARDASIL 9 the patient experienced a full onset seizure. The outcome of seizure was unknown. The relatedness between GARDASIL 9 and the event was not reported. Upon internal review, the event of a full onset seizure was considered to be medically significant. Additional information is not expected as there were no patient's or physician's contact details.
This spontaneous report was received from a doctor of pharmacy concerning a patient of unknown age and gender. On an unknown date, the patient was vaccinated with a dose (standard dose per hospital protocol) of PNEUMOVAX23 (lot number and expiry date reported as H018380 and 12-MAR-2014 respectively), intramuscularly per hospital protocol. No concomitant medications were reported. On an unknown date, the patient experienced increased level of cellulitis that occurred within the past few months. The patient sought medical attention (patient already in the hospital, reason for hospitalization and hospitalization date unspecified). Pharmacist did not known if the event prolonged the stay of the patient in the hospital. The pharmacist did not have a lot of information for the report because she received this information from her pharmacy supervisor who received it from a nurse. Pharmacist requested for a lot check to see if there were an increase level of cellulitis associated with this lot number. The outcome of increased level of cellulitis was unknown. The relatedness for increased level of cellulitis was unknown for PNEUMOVAX23. Additional information has been requested.
Redness noted approximately 4x4 inches.  Pt instructed to apply ice to left thigh.
18 year old patient received 1mL adult dose instead of pediatric dose. No adverse symptoms.
Patient notified of vaccine given 7 days early.  Pt stated was doing fine and not feeling sick.  No adverse reactions.